patent.fyi
Applications  /  US 2026/0355224
United States Patent Application Publication

US 2026/0355224 A1

Published
Nov 12, 2026
Filed
Jun 12, 2026
Earliest date on the face
Jan 30, 2019
Classification
A61K 31/675
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Slow release from the wall

What ifWhat if the slow-release fraction resided in the wall of a hollow nanoparticle?
Claim language“a core comprising a controlled release component”

A hollow polymer nanocapsule holds the slow-release fraction within its solid wall and water in its central cavity. Water enters the wall, and the dissolved compound diffuses outward through the polymer.

1.1Slow release from separate granules

What ifWhat if separate coated granules supplied the slow-release fraction?
Claim language“a core comprising a controlled release component”

A capsule contains a powder that disperses into nanoparticles and a second fraction made of coated granules. Water penetrates the ethylcellulose coating on the granules, and dissolved compound diffuses through water-filled pores.

1.1Timing set by divided doses

What ifWhat if separately administered immediate-release doses supplied the later portions?
Claim language“a controlled release component”

Each unit contains nanoparticles with a water-soluble core that dissolves on contact with fluid. The units are administered at preset intervals, and each administration supplies a separate pulse.

1.2Rapid release from exposed pores

What ifWhat if exposed pores in a shell-free nanoparticle carried the immediate-release fraction?
Claim language“an outer shell comprising an immediate release component”

An uncoated porous polymer particle holds readily soluble material as deposits on the walls of open pores. Fluid enters the pores directly and dissolves those deposits, while compound embedded in the polymer matrix diffuses out more slowly.

1.2Rapid release from separate granules

What ifWhat if separate soluble granules supplied the immediate-release fraction?
Claim language“an outer shell comprising an immediate release component”

A capsule contains controlled-release nanoparticles and separate water-soluble granules containing the rapid-release fraction. The capsule opens in fluid, which dissolves the granules while release from the nanoparticles continues.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Two-stage corrosion inhibitor for primer

A mesoporous silica core holds benzotriazole in its pores, and a water-soluble polyvinyl alcohol shell contains sodium benzoate. The particles are dispersed in a solventborne acrylic primer applied to steel. Water entering a coating defect dissolves the shell and releases sodium benzoate, while benzotriazole diffuses out of the wetted pores over a longer interval.

Component substitution

Silica pores meter core release

Mesoporous silica serves as the controlled-release core in place of a polymer matrix. Riboflavin is loaded by soaking the silica in an aqueous solution and drying it, and a thin mannitol shell containing riboflavin is deposited by spray drying. On rehydration, the mannitol dissolves and releases its riboflavin first, while riboflavin held inside the silica pores diffuses into the surrounding liquid.

Brittle shell releases during rubbing

A porous silica core holds fragrance oil, and a brittle cross-linked acrylic shell contains a second portion of the same oil in dispersed droplets. The particles are incorporated into a waterborne coating and dried on paper. Rubbing the surface fractures the shell and exposes its droplets for immediate evaporation, while oil in the exposed core pores diffuses out and evaporates more slowly.

Parameter or scale variation

Shell thickness sets the early dose

Each particle has a 240 nm ethylcellulose core containing caffeine and a water-soluble shell of polyvinyl alcohol and caffeine. Two batches use nominal dry shell thicknesses of 10 nm and 25 nm, giving outer diameters of 260 nm and 290 nm. Both batches use the same shell composition, and the thicker shell supplies more caffeine per particle during initial dissolution. The ethylcellulose core then releases its caffeine by diffusion.

Combination with existing systems

Core-shell particles in an oral film

Lipid cores containing caffeine are coated with a water-soluble shell containing caffeine and mannitol. The dry particles are dispersed in an ethanol-based hydroxypropyl cellulose casting solution and incorporated into an oral film by solvent evaporation. Saliva dissolves the film and the particle shells, releasing the shell dose and dispersing the lipid cores. The cores continue to release caffeine into the surrounding fluid.

Automated or data-driven variant

Automated feedback tunes shell deposition

A continuous mixer forms ethylcellulose cores containing caffeine, and a downstream spray dryer applies a water-soluble shell containing a second portion of caffeine. An automated flow-through dissolution sampler measures caffeine released at one minute and sixty minutes using liquid chromatography. A controller adjusts the shell-solids feed for subsequent material using the one-minute result and flags material whose sixty-minute release falls outside the specified range.

Specific version of a part

Rapid release from tablet matrix

A polyethylene glycol layer stabilizes the nanoparticle surface during dispersion. A soluble fraction of the compound sits in the tablet matrix, and a swelling disintegrant breaks the tablet apart to expose that fraction to fluid.

Hydrolyzing polyester matrix core

A poly(lactide-co-glycolide) core contains the compound dispersed through a solid polyester matrix. Water enters the core, and diffusion and polymer hydrolysis govern release.

Solid lipid matrix core

A glyceryl behenate core contains the compound within a solid lipid matrix. The compound partitions into surrounding fluid as it diffuses through the matrix.

Water-soluble polymer shell

A dry polyvinylpyrrolidone shell contains a soluble fraction of the compound. On contact with fluid, the polymer dissolves and releases that fraction.

Dissolving sugar glass shell

An amorphous trehalose shell contains the compound dispersed in a dry sugar glass. Fluid dissolves the shell and carries the compound into the surrounding liquid.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2008/0299188 A1
Published
Dec 4, 2008
Filed
May 14, 2007
Class
A61K 9/52
Document BUS 2014/0065216 A1
Published
Mar 6, 2014
Filed
Sep 3, 2013
Class
A61K 9/2806
Claim 1
Document A
Document B
1.1a core comprising a controlled release component; and
In one embodiment, the dosage form comprises an immediate release portion and an enteric coated sustained release core, wherein the sustained release core is in the form of a matrix controlled release device and the immediate release portion is in the form of an immediate release coating.
A · US 2008/0299188 A1 · ¶ 157
1.2an outer shell comprising an immediate release component,
An immediate release coating 16 comprising the drug and optional excipients, as discussed above surrounds the enteric coating 14.
A · US 2008/0299188 A1 · ¶ 157
In one embodiment, a pH agent (either an acid or base or neutral agent) together with a rapidly dissolving polymer is coated on the exterior of the dosage form. The polymer dissolves promptly when wetted by saliva and rapidly releases the pH agent and thereby rapidly modulates the pH of the saliva.
B · US 2014/0065216 A1 · ¶ 10

An empty cell means only that no passage was reproduced there.

Statements in these documents
Accordingly, there is a continuing need for a controlled release oral dosage form that provides effective concentration of drug in the blood for relatively long periods of time for low-solubility drugs that are poorly absorbed over at least a portion of the gastrointestinal tract and that have a relatively short biological half life.
A · US 2008/0299188 A1 · ¶ 4
The primary goal of a controlled release dosage form is to maintain the desired therapeutic effect for an extended period of time.
A · US 2008/0299188 A1 · ¶ 2
The rapid release coating contains a material having a property of rapidly modulating a pH of bodily fluids in which the material comes in contact in a direction towards a pH which is most suitable for absorption considering the pKa of the at least one bioactive agent or alternatively towards a pH which is most suitable for retardation of absorption.
B · US 2014/0065216 A1 · ¶ 3
This methodology would apply to all solid dosage units including without limitation capsules, liquigels, tablets, thin film, sheet, orally dissolving tablets, vaginal rings, suppositories, pessaries, topicals, microparticles, particles and the like.
B · US 2014/0065216 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0355224 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355224/, SHA-256 636e9f2bdcdcce9b0508bc5b843f26affde1b0662adc7a7c52204c67077ce907
First published
Permanent addresshttps://patent.fyi/US20260355224/
Content fingerprint (SHA-256)636e9f2bdcdcce9b0508bc5b843f26affde1b0662adc7a7c52204c67077ce907
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi